A Natural Choice
Expressed in a human cell line.
B-domain deleted.
No chemical modifications.

Previously Treated Patients (PTPs)

PTPs can benefit from the safety and bleed protection
of NUWIQ

Portrait of group of friends looking the camera in the street.

Previously Untreated Patients (PUPs)

The NuProtect clinical trial is studying the safety and effectiveness of NUWIQ in over 100 PUPs with severe
Hemophilia A.

Learn More

Reading with mom! African descent mother, child and book. Home.

Free Trial

A great opportunity for Hemophilia A patients and their providers to experience the safety, effectiveness, and convenience of NUWIQ
at no cost.

Learn More

Co-Pay Assistance

The Octapharma Co-Pay Assistance Program can provide savings on some of the costs associated
with your treatment.

Learn More

Young man hiking pulls out hand to get assistance

NUWIQ has been a game changer for me. It fits in with my busy lifestyle. I’m totally confident that NUWIQ has me covered.
Edgar Martinez
Father and High School Football Coach/St. Augustine, FL
Read More

Indications and Important Safety Information for NUWIQ [Antihemophilic Factor (Recombinant)]

Please see NUWIQ full Prescribing Information. Instructions For Use

Indications and Important Safety Information for NUWIQ [Antihemophilic Factor (Recombinant)]

Please see NUWIQ full Prescribing Information. Instructions For Use

Indications and Use

NUWIQ^® is a recombinant antihemophilic factor [coagulation factor VIII (Factor VIII)] indicated in adults and children with Hemophilia A for on-demand treatment and control of bleeding episodes, perioperative management of bleeding, and routine prophylaxis to reduce the frequency of bleeding episodes. NUWIQ^® is not indicated for the treatment of von Willebrand Disease.

Contraindications and Adverse Events

NUWIQ is contraindicated in patients who have manifested life-threatening hypersensitivity reactions, including anaphylaxis, to the product or its components.

The most frequently occurring adverse reactions (>0.5%) in clinical trials were paresthesia, headache, injection site inflammation, injection site pain, non-neutralizing anti-Factor VIII antibody formation, back pain, vertigo, and dry mouth.

Warnings and Precautions

Hypersensitivity reactions, including anaphylaxis, are possible with NUWIQ. Early signs of hypersensitivity reactions that can progress to anaphylaxis may include angioedema, chest tightness, dyspnea, wheezing, urticaria, or pruritus. Immediately discontinue administration and initiate appropriate treatment if hypersensitivity reactions occur.

The formation of neutralizing antibodies (inhibitors) to Factor VIII can occur following the administration of NUWIQ. Monitor all patients for the development of Factor VIII inhibitors by appropriate clinical observations and laboratory tests. If the plasma Factor VIII level fails to increase as expected, or if bleeding is not controlled after NUWIQ administration, suspect the presence of an inhibitor (neutralizing antibody).

Please See NUWIQ full Prescribing Information. Instructions For Use

A Natural ChoiceExpressed in a human cell line. B-domain deleted. No chemical modifications.

Previously Treated Patients (PTPs)

Previously Untreated Patients (PUPs)

Free Trial

Co-Pay Assistance

A Natural Choice
Expressed in a human cell line.
B-domain deleted.
No chemical modifications.